acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

News

Guidance

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) (&quot;CERo&quot;), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the

CERo Therapeutics Announces Submission Of IND Clinical Hold Complete Response Letter; Adjusts Previous Guidance About Potential Entry Into The Clinic From 2024 To Early 2025; Recently Disclosed Our Cash Balance Of $3.2M As Of September 30, 2024 - CERo Therapeutics Hldgs (NASDAQ:CERO)

Benzinga Newsdesk

CERo Therapeutics Hldgs

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the

CERO

CERo Therapeutics Announces Submission Of IND Clinical Hold Complete Response Letter; Adjusts Previous Guidance About Potential Entry Into The Clinic From 2024 To Early 2025; Recently Disclosed Our Cash Balance Of $3.2M As Of September 30, 2024

Comments